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Abstract
Mitochondrial DNA disease is one of the most common groups of inherited neuromuscular disorders and frequently associated with marked
phenotypic and genotypic heterogeneity. We describe an adult patient who initially presented with childhood-onset ataxia without a family history
and an unremarkable diagnostic muscle biopsy. Subsequent multi-system manifestations included basal ganglia calcification, proteinuria, cataract
and retinitis pigmentosa, prompting a repeat muscle biopsy that showed features consistent with mitochondrial myopathy 13 years later. She had
a stroke with restricted diffusion change in the basal ganglia and internal capsule at age 44 years. Molecular genetic testing identified a
previously-reported pathogenic, heteroplasmic mutation in the mitochondrial-encoded transfer RNA tryptophan (MT-TW) gene which based on
family studies was likely to have arisen de novo in our patient. Interestingly, we documented an increase in the mutant mtDNA heteroplasmy level
in her second biopsy (72% compared to 56%), reflecting the progression of clinical disease.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/
by/4.0/).
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1. Introduction
Mitochondrial DNA (mtDNA) disease is clinically
heterogeneous with variable age of onset ranging from fatal,
infantile-onset presentations such as Leigh syndrome to late-
adult onset chronic progressive external ophthalmoplegia
(CPEO). Although neurological features are prominent in most
cases, there is often multi-system involvement [1,2]. Since the
first pathogenic mutations were identified in the mitochondrial
genome in 1988, more than 300 different single nucleotide
variants have been reported in association with human disease.
Whilst common point mutations such as the m.3243A>G
mutation and three primary Leber hereditary optic neuropathy
(LHON) mutations are prevalent in the population and have
been extensively studied [3], novel and/or rare pathogenic
variants are often reported in single or small numbers of family
pedigrees and therefore the spectrum of phenotype and severity
is poorly understood.
The m.5540G>A mutation in the mitochondrial (mt-)
tRNATrp (MT-TW) gene has been associated with refractory
epilepsy, ataxia, neuropathy, cognitive impairment, myopathy
and pigmentary retinopathy [4,5]. Here we report an adult
patient who harbours this mutation but displays additional
clinical features that have not been previously described.
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2. Patient and methods
2.1. Case report
A 45 year old Caucasian woman had a long history of falls
due to progressive ataxia since the age of 10. Her birth history
and early developmental milestones were unremarkable. She
completed secondary school and achieved basic qualification
in education but was never good in sport. At age 17, she
developed poor night vision and bilateral hearing deficit.
She had bilateral cataract surgeries and used hearing aids at
age 31. She experienced fatigue but did not complain of overt
muscle weakness. She developed moderately heavy proteinuria
(Albumin to creatinine ratio 152) but with normal serum
albumin level since age 43.
Her mother has glucose intolerance and her father has
sensorineural deafness. There was no family history of
neurological disorder, eye problem, or cardiomyopathy. All her
siblings are fit and well, and as such did not request molecular
genetic testing.
Her resting blood lactate level was normal and creatine
kinase (CK) level was 276 U/L. There was no glucose
intolerance. Her renal function declined gradually and the
current urea and creatinine levels were 11 mmol/L and
97 μmol/L, respectively (compared to 5 mmol/L and
88 μmol/L 8 years ago). Renal ultrasound demonstrated loss of
cortico-medullary differentiation, increased echogenicity and
asymmetrical kidney size (left kidney measured 7.9 cm, right
kidney 10.2 cm). Nerve conduction studies were normal at age
28. Her initial CT head and cranial MRI showed bilateral basal
ganglia calcification, periventricular white matter changes and
cerebral and cerebellar atrophy (Fig. 1A and B).
Clinical examination (at age 43) revealed pigmentary
retinopathy, deafness, bilateral pes cavus, areflexia in the lower
limbs, mild myopathy with MRC grade 4+/5, cerebellar signs,
loss of proprioception sense and vibration sense in the lower
limbs and broad-based gait.
She was admitted to hospital with left sided weakness and
loss of mobility at age 44. The neurological deficit evolved over
12 hours. There was no associated speech disturbance or visual
field defect. Her ECG showed sinus rhythm and she had
hypertension. Cranial MRI revealed acute changes involving
the right internal capsule and lentiform nucleus (Fig. 1C and
D). She was treated with antiplatelet, angiotensin converting
enzyme inhibitor, oral L-arginine and co-enzyme Q10. Further
cardiac assessment including 48 hour ambulatory ECG and
transthoracic echocardiogram was unremarkable. Despite a
period of rehabilitation, she only made partial recovery and
required walking aid for mobility. In addition, the cerebellar
syndrome has progressed with worsening dysarthria and ataxia
on the last clinic review.
2.2. Histopathology, biochemistry and molecular genetic
studies
This patient underwent two muscle biopsies, the first at the
age of 28 years and a second biopsy at 41 years of age. Both
muscle samples were subjected to standard histopathological
analyses. Informed consent was obtained from the patient
and her mother for genetic testing. Total DNA from blood
(leucocytes), muscle, saliva and urine was extracted by standard
procedures. Long-range PCR of muscle DNA was performed to
screen samples for large-scale mtDNA rearrangements. The
methods for sequencing of entire mtDNA and quantitative
pyrosequencing of mtDNA heteroplasmy level have been
described elsewhere [6]. In addition to the patient’s samples,
blood, urine and saliva samples from the patient’s mother were
also obtained for mitochondrial genetic studies.
3. Results
The first muscle biopsy was initially reported as normal
histopathologically, whilst respiratory chain enzyme studies
also failed to show any major enzyme defect (data not shown).
A repeat muscle biopsy (interval of 13 years) showed small,
round fibres with tiny vacuoles consistent with lipid content
(confirmed by Oil Red O staining), occasional ragged-red
fibres (RRFs) together with cytochrome c oxidase (COX)-
intermediate and COX-deficient fibres (Fig. 2). A retrospective
review of the first muscle biopsy revealed subtle but definitive
focal COX-deficiency (see Fig. 2D).
Screens for common mtDNA mutations including
m.3243A>G, m.8344A>G, m.8993T>C/G and m.13513G>A
were negative whilst long-range PCR protocols failed to
detect any evidence of large-scale mtDNA deletions.
Sequencing of the entire mitochondrial genome in muscle led to
the identification of a previously-reported mutation in the
mt-tRNATrp (MT-TW) gene – m.5540G>A. The mutation load
was heteroplasmic and quantified by pyrosequencing at levels
of 56% and 72% in the first and second muscle biopsies
Fig. 1. Neuroimaging results (A) CT head showed bilateral, symmetrical
basal ganglia calcification. (B) Sagittal view of cranial MRI showed significant
cerebral and cerebellar atrophy at the age of 39 years. (C) Diffusion-weighted
imaging showed restricted diffusion in the right internal capsule and lentiform
nucleus with corresponding low signal change in (D)ADC map at the age of 44
years.
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respectively, 12% in blood, 28% in saliva and 34% in urine
DNA samples (Fig. 2A).
The m.5540G>A mutation was not detected in any samples
(blood, urine and saliva) obtained from the patient’s mother
(Fig. 2A).
4. Discussion
Here we report a female patient who harboured the
previously-described heteroplasmic m.5540G>A mutation and
presented with a childhood-onset slowly progressive cerebellar
ataxia complicated by multi-system manifestation. Similar to
previous reports [4,5,7], our patient had sensorineural deafness,
pigmentary retinopathy, cerebellar syndrome, peripheral
neuropathy and bilateral basal calcification, cerebral and
cerebellar atrophy. The additional clinical features in this
case include: (1) early-onset, bilateral cataracts; (2) renal
involvement manifesting with heavy proteinuria and
hypertension without overt nephrotic syndrome; (3) acute,
unilateral ischaemic changes in the basal ganglia.
Myopathy appears not to be a prominent clinical feature
associated with this specific mtDNA mutation. There are
a few published examples [8,9] of a progression in the
histopathological changes and the increase in the mutant
mtDNA heteroplasmy level such as we demonstrated between
the two diagnostic muscle biopsies. Our new data support the
general idea that severity of the muscle phenotype increases
with mutant load, as a result of clonal expansion [10]. Whilst it
is also possible that the difference simply reflects heterogeneity
in mutant load in different regions of her muscle, we are not
aware of any report of such a large difference in muscle samples
taken at the same time. We also found that mutant mtDNA
heteroplasmy levels in other non-invasively obtained tissues
were much lower than the muscle, similar to previous reports of
a mutation hierarchy between mitotic and post-mitotic tissues
[5], and consistent with a progressive loss of mutant mtDNA
from blood [11]. We would speculate that a higher mutant
heteroplasmy is present in the central nervous system given
the patient has early-onset ataxia and has had a stroke.
Furthermore, we believe that the m.5540G>A mutation has
arisen de novo in our patient as it was not detected in multiple
tissues taken from the patient’s mother although the possibility
of germline mosaicism in her mother’s oocytes [12] could not
be excluded. We have previously shown that the level of
mutant mtDNA in blood is lower in sporadic compared with
transmitted pathogenic mtDNA mutations [13]. The relatively
low mutant load in blood DNA (12%) is entirely consistent with
sporadic occurrence.
The mitochondrial genome is enormously susceptible to
mutation [14]. Elliot et al. have estimated that the de novo
mutation rate in ten common pathogenic mtDNA variants is
107/100,000 live births (95% CI = 87–127) [15]. More recently,
a large case series shows the de novo frequency is up to 25%
in patients with the mtDNA mutations, with a low recurrence
risk [16]. Furthermore, six of the fifteen MT-TW pathogenic
gene variants (including the m.5540G>A mutation) have been
reported to occur as de novo mutations (Supplementary
Table S1). These findings have important implications for
clinical practice; first, the absence of family history of
maternally-inherited multisystem disease should not preclude
the testing for mtDNA mutations and second, carrier testing
should be performed on at least two tissues to mitigate the risk
of false negative results due to the variable segregation of
mutant mtDNA heteroplasmy in different tissues. Thirdly,
the risk of recurrence in further siblings is low for de novo
mutations [16].
The presence of chronic proteinuria and renal insufficiency
without electrolyte imbalance is suggestive of glomerular
dysfunction, probably caused by the underlying mitochondrial
Fig. 2. mtDNAmutation analysis in the patient and her mother (A) Family tree identifying the proband (highlighted by an arrow) with the m.5540G>Amutation.
Analysis of several samples from the patient’s clinically-unaffected mother strongly suggested that the m.5540G>Amutation has arisen de novo. (B–D)A first muscle
biopsy, performed at the age of 28 years, shows normal muscle architecture in the H&E (B) and modified Gomori trichrome (C) stains and only occasional
COX-deficient fibres (asterisked) identified following sequential COX/SDH histochemistry (D). (E–G) A second muscle biopsy, performed 13 years later, shows
slightly rounded muscle fibres (E), an occasional ragged-red fibre (**) and an apparent increase in the number of COX-deficient fibres and those with diminished
COX reactivity (asterisked, G).
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defect in our patient, although renal biopsy has not been
undertaken to exclude other aetiologies. Renal manifestations
including Fanconi syndrome, focal segmental glomerulosclerosis
and end-stage renal failure have been recognised in patients with
pathogenic mitochondrial tRNAmutations although interestingly
tubulopathy appears more commonly associated with primary
single, large-scale deletion of mtDNA [17,18].
Classical stroke-like episodes in mitochondrial disease
typically manifest with evolving encephalopathy, focal seizure
and neurological deficit with cortical and subcortical changes
identified in the brain imaging [19]. Although symmetrical
cystic changes in basal ganglia are common in patients with
Leigh syndrome, unilateral acute changes in the deep nuclei,
such as those observed in our patient, are rare. Her presentation
of hemiparesis has been attributed to be a metabolic event
because of the evolving nature of the clinical presentation.
However, a lacunar stroke remains a possibility. L-arginine
and co-enzyme Q10 were commenced during the hospital
admission but we have not observed dramatic improvement of
the neurological deficit.
In conclusion, our findings broaden the clinical phenotype
associated with the m.5540G>A mutation which in our patient
is likely to have arisen sporadically and manifests marked tissue
segregation.
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